KANSAS CITY, MO – September 4, 2013 – Children's Mercy Hospital in Kansas City, Mo. has received a research grant for more than $5 million from the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Human Genome Research Institute at the National Institutes of Health. The grant allows Children's Mercy to assess the benefits of making STAT-Seq, currently the fastest whole genome analysis in the world, routine for diagnosis of acutely ill infants in neonatal intensive care units (NICUs).
"We are very grateful to receive this pioneering federal award," said Dr. Stephen Kingsmore, Director of the Center for Pediatric Genomic Medicine at Children's Mercy and Principal Investigator of the grant. "We believe that 30 percent of the babies in our NICUs are likely to benefit from next-day genome sequencing. This grant will generate the critical data to guide the use of rapid genome sequencing in the diagnosis and treatment of acutely ill babies."
The award, "Clinical and Social Implications of 2-day Genome Results in Acutely Ill Newborns," will fund studies to improve the speed and cost-effectiveness of STAT-Seq, and to evaluate the benefits, and potential harms, of rapid genome sequencing in newborns in nurseries and intensive care units.
"More than 20 percent of infant deaths are caused by congenital malformations, deformations and chromosomal abnormalities caused by genetic illnesses," said Dr. Howard Kilbride, Director of the Division of Neonatology for Children's Mercy. "Families want answers, and they want them quickly. This technology – and this grant, in particular – will help make that happen."
STAT-Seq is being developed by the hospital's Center for Pediatric Genomic Medicine in collaboration with Illumina Inc., and uses rapid whole genome sequencing to help physicians make a timely diagnosis in newborns who are acutely ill, likely with a genetic disease. STAT-Seq sets a new standard for speed, taking less than 50 hours from test order to the delivery of an interim report to a physician.
Children Mercy's research under this grant will in part be made possible by industry-leading newborn screening technologies from PerkinElmer, whose solutions have helped screen more than 400 million babies worldwide for a variety of life-threatening diseases.
Visit http://www.pediatricgenomicmedicine.com for more information on the Center for Pediatric Genomic Medicine.
About Children's Mercy Hospital
Children's Mercy Hospital, located in Kansas City, Mo., is one of the nation's top pediatric medical centers. The 354-bed hospital provides care for children from birth through the age of 21, and has been ranked by U.S. News & World Report as one of "America's Best Children's Hospitals" and recognized by the American Nurses Credentialing Center with Magnet designation for excellence in nursing services. Its faculty of 600 pediatricians and researchers across more than 40 subspecialties are actively involved in clinical care, pediatric research, and educating the next generation of pediatric subspecialists. For more information about Children's Mercy and its research, visit childrensmercy.org or download our mobile phone app CMH4YOU for all phone types. For breaking news and videos, follow us on Twitter, YouTube and Facebook.
About The Center for Pediatric Genomic Medicine at Children's Mercy Hospital
The first of its kind in a pediatric setting, The Center for Pediatric Genomic Medicine combines genome, computational and analytical capabilities to bring new diagnostic and treatment options to children with genetic diseases. As a leading researcher in pediatric genomic medicine, Stephen Kingsmore, M.B. Ch.B., D.Sc., FRCPath, was named to Medscape's Best Physicians list and his team's STAT-Seq test was one of TIME magazine's Top 10 Medical Breakthroughs of 2012. For more information about STAT-Seq, TaGSCAN, diagnostic tests and current research, visit http://www.pediatricgenomicmedicine.com.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.